A first-in-human study from researchers from Memorial Sloan Kettering Cancer Center and The Rockefeller University demonstrated that a re-engineered CD40 antibody delivered directly into tumors can trigger systemic immune responses without the severe side effects that doomed earlier versions of the treatment.

The study , published in Cancer Cell , tested a drug in 12 patients with advanced cancers that had spread to the skin, including melanoma, breast cancer and kidney cancer. Six patients saw their tumors shrink, including two patients who achieved complete responses that lasted more than a year. The complete response was in part due to the treatment creating immune structures inside tumors that helped the body fight cancer beyond the injection site.

“Seeing these significant shrin

See Full Page